跳至主要内容
临床试验/NCT01630174
NCT01630174Unknown不适用

Phase I Study of Concurrent Selective Lymph Node Late Course Accelerated Hyper-fractionated Radiotherapy and Pemetrexed, Cisplatin for Locally Advanced Esophageal Squamous Cell Carcinoma

Shandong Cancer Hospital and Institute1 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2009年10月最近更新:
适应症

试验速览

阶段
不适用
发起方
入组人数
30
试验地点
1

研究概览

简要总结

To evaluate the effect of concomitant late course accelerated hyperfractionation radiochemotherapy with pemetrexed and cisplatin in patients with esophagus cancer

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Signed informed consent; 2.Acquired pathological diagnosis; 3.Life expectancy≥6 months; 4.Age:18-75 years, male or female; 5.General state of health: ECOG 0-1 grade; 6.Without any chemotherapy or radiotherapy; 7.Subjects meet the following criteria for the clinical laboratory:HG≥100g/L, WBC≥3.5X109 /L, neutrophilic leukocyte≥1.5X109,PLT100X109 /L。CR≤1.5 x N,TB≤2.5XN,AST and ALT≤2.5xN,AKP≤2.5XN.

排除标准

  • 1.Serious infection; 2.Uncontrollable diabetes; 3.Other serious diseases, such as myocardial infarction in 6 months;
  • Participated other clinical trials in 4 weeks or at present

研究者

发起方
Shandong Cancer Hospital and Institute
申办方类型
Other
责任方
Principal Investigator
主要研究者

Baosheng Li

Ph.D.

Shandong Cancer Hospital and Institute

研究点 (1)

Loading locations...

相似试验